# Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

> **NCT05918978** · PHASE2 · TERMINATED · sponsor: **argenx** · enrollment: 33 (actual)

## Conditions studied

- Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

## Interventions

- **DRUG:** Efgartigimod

## Key facts

- **NCT ID:** NCT05918978
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-20
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918978, "Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05918978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*